342 related articles for article (PubMed ID: 24840876)
1. Enhanced bleaching treatment: opportunities for immune-assisted melanocyte suicide in vitiligo.
Webb KC; Eby JM; Hariharan V; Hernandez C; Luiten RM; Le Poole IC
Exp Dermatol; 2014 Aug; 23(8):529-33. PubMed ID: 24840876
[TBL] [Abstract][Full Text] [Related]
2. Monobenzyl ether of hydroquinone and 4-tertiary butyl phenol activate markedly different physiological responses in melanocytes: relevance to skin depigmentation.
Hariharan V; Klarquist J; Reust MJ; Koshoffer A; McKee MD; Boissy RE; Le Poole IC
J Invest Dermatol; 2010 Jan; 130(1):211-20. PubMed ID: 19657355
[TBL] [Abstract][Full Text] [Related]
3. Depigmentation Therapies for Vitiligo.
Grimes PE; Nashawati R
Dermatol Clin; 2017 Apr; 35(2):219-227. PubMed ID: 28317530
[TBL] [Abstract][Full Text] [Related]
4. Accelerating bleaching in vitiligo: balancing benefits versus risks.
Seneschal J; Boniface K; Ezzedine K; Taieb A
Exp Dermatol; 2014 Dec; 23(12):879-80. PubMed ID: 25039467
[TBL] [Abstract][Full Text] [Related]
5. Targeting melanocyte and melanoma stem cells by 8-hydroxy-2-dipropylaminotetralin.
Bonchak JG; Eby JM; Willenborg KA; Chrobak D; Henning SW; Krzywiec A; Johnson SL; Le Poole IC
Arch Biochem Biophys; 2014 Dec; 563():71-8. PubMed ID: 25132642
[TBL] [Abstract][Full Text] [Related]
6. Preferential secretion of inducible HSP70 by vitiligo melanocytes under stress.
Mosenson JA; Flood K; Klarquist J; Eby JM; Koshoffer A; Boissy RE; Overbeck A; Tung RC; Le Poole IC
Pigment Cell Melanoma Res; 2014 Mar; 27(2):209-20. PubMed ID: 24354861
[TBL] [Abstract][Full Text] [Related]
7. Depigmentation therapies for normal skin in vitiligo universalis.
AlGhamdi KM; Kumar A
J Eur Acad Dermatol Venereol; 2011 Jul; 25(7):749-57. PubMed ID: 21054565
[TBL] [Abstract][Full Text] [Related]
8. Retinoic acid synergistically enhances the melanocytotoxic and depigmenting effects of monobenzylether of hydroquinone in black guinea pig skin.
Kasraee B; Fallahi MR; Ardekani GS; Ebrahimi S; Doroudchi G; Omrani GR; Handjani F; Amini M; Tanideh N; Haddadi M; Nikbakhsh M; Jahanbani S; Tran C; Sorg O; Saurat JH
Exp Dermatol; 2006 Jul; 15(7):509-14. PubMed ID: 16761959
[TBL] [Abstract][Full Text] [Related]
9. Mutant HSP70 reverses autoimmune depigmentation in vitiligo.
Mosenson JA; Zloza A; Nieland JD; Garrett-Mayer E; Eby JM; Huelsmann EJ; Kumar P; Denman CJ; Lacek AT; Kohlhapp FJ; Alamiri A; Hughes T; Bines SD; Kaufman HL; Overbeck A; Mehrotra S; Hernandez C; Nishimura MI; Guevara-Patino JA; Le Poole IC
Sci Transl Med; 2013 Feb; 5(174):174ra28. PubMed ID: 23447019
[TBL] [Abstract][Full Text] [Related]
10. Monobenzylether of hydroquinone. A retrospective study of treatment of 18 vitiligo patients and a review of the literature.
Mosher DB; Parrish JA; Fitzpatrick TB
Br J Dermatol; 1977 Dec; 97(6):669-79. PubMed ID: 603749
[TBL] [Abstract][Full Text] [Related]
11. HSP70i accelerates depigmentation in a mouse model of autoimmune vitiligo.
Denman CJ; McCracken J; Hariharan V; Klarquist J; Oyarbide-Valencia K; Guevara-Patiño JA; Le Poole IC
J Invest Dermatol; 2008 Aug; 128(8):2041-8. PubMed ID: 18337834
[TBL] [Abstract][Full Text] [Related]
12. Effective melanoma immunotherapy in mice by the skin-depigmenting agent monobenzone and the adjuvants imiquimod and CpG.
van den Boorn JG; Konijnenberg D; Tjin EP; Picavet DI; Meeuwenoord NJ; Filippov DV; van der Veen JP; Bos JD; Melief CJ; Luiten RM
PLoS One; 2010 May; 5(5):e10626. PubMed ID: 20498710
[TBL] [Abstract][Full Text] [Related]
13. 4-Tertiary butyl phenol exposure sensitizes human melanocytes to dendritic cell-mediated killing: relevance to vitiligo.
Kroll TM; Bommiasamy H; Boissy RE; Hernandez C; Nickoloff BJ; Mestril R; Caroline Le Poole I
J Invest Dermatol; 2005 Apr; 124(4):798-806. PubMed ID: 15816839
[TBL] [Abstract][Full Text] [Related]
14. Optimization of Monobenzone-Induced Vitiligo Mouse Model by the Addition of Chronic Stress.
Dong J; Lai Y; Zhang X; Yue Y; Zhong H; Shang J
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108153
[TBL] [Abstract][Full Text] [Related]
15. Effects of Monobenzyl ether of hydroquinone on 3T3 mouse fibroblast viability and ultrastructure.
Erdoğan A; Mutlu HS; Doğan S; Kotil T
Ultrastruct Pathol; 2021 Nov; 45(6):384-390. PubMed ID: 34875974
[TBL] [Abstract][Full Text] [Related]
16. A mouse model of vitiligo induced by monobenzone.
Zhu Y; Wang S; Xu A
Exp Dermatol; 2013 Jul; 22(7):499-501. PubMed ID: 23800067
[TBL] [Abstract][Full Text] [Related]
17. Rapid repigmentation after depigmentation therapy: vitiligo treated with monobenzyl ether of hydroquinone.
Oakley AM
Australas J Dermatol; 1996 May; 37(2):96-8. PubMed ID: 8687336
[TBL] [Abstract][Full Text] [Related]
18. The nuclear factor (erythroid-derived 2)-like 2 (NRF2) antioxidant response promotes melanocyte viability and reduces toxicity of the vitiligo-inducing phenol monobenzone.
Arowojolu OA; Orlow SJ; Elbuluk N; Manga P
Exp Dermatol; 2017 Jul; 26(7):637-644. PubMed ID: 28370349
[TBL] [Abstract][Full Text] [Related]
19. Chemical induced pathognomonic features observed in human vitiligo are mediated through miR-2909 RNomics pathway.
Kaushik H; Kaul D; Kumaran MS; Parsad D
J Dermatol Sci; 2020 Nov; 100(2):92-98. PubMed ID: 33039241
[TBL] [Abstract][Full Text] [Related]
20. Topical application of bleaching phenols; in-vivo studies and mechanism of action relevant to melanoma treatment.
Hariharan V; Toole T; Klarquist J; Mosenson J; Longley BJ; Le Poole IC
Melanoma Res; 2011 Apr; 21(2):115-26. PubMed ID: 21317816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
